Unknown

Dataset Information

0

Primary Orthostatic Tremor: Experience of Perampanel Use in 20 Patients.


ABSTRACT: Background:Primary orthostatic tremor (POT) is a rare disorder for which current treatments are largely ineffective. Following up on our recent report of complete resolution of POT symptoms in a patient using low doses of perampanel, we describe our experience of perampanel in 20 patients. Methods:Twenty patients whose neurologists prescribed perampanel were recruited. Initial dose was 2 mg/day, which was increased to 4 mg/day after the first month. Treatment efficacy was self-scored from +3 to -3 at 1 and 3 months. Results:Eight patients withdrew due to adverse effects. Of the 12 patients who completed the study, 92% indicated that their POT symptoms had improved after 1 month, with 75% indicating moderate to marked improvement (mean score 1.9 ± 0.9). This improvement was not sustained by follow-up at 3 months (mean score 0.9 ± 1.3). A rebound of POT symptoms that lasted 2-6 weeks was observed in most patients who withdrew. Discussion:Our experience with this series of cases points to the potential of low-dose perampanel as a treatment for POT, although poor tolerance and the possibility of a non-persistent therapeutic benefit need to be considered. Controlled studies are needed to confirm these findings.

SUBMITTER: Gironell A 

PROVIDER: S-EPMC6800298 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Primary Orthostatic Tremor: Experience of Perampanel Use in 20 Patients.

Gironell Alexandre A   Marín-Lahoz Juan J  

Tremor and other hyperkinetic movements (New York, N.Y.) 20191014


<h4>Background</h4>Primary orthostatic tremor (POT) is a rare disorder for which current treatments are largely ineffective. Following up on our recent report of complete resolution of POT symptoms in a patient using low doses of perampanel, we describe our experience of perampanel in 20 patients.<h4>Methods</h4>Twenty patients whose neurologists prescribed perampanel were recruited. Initial dose was 2 mg/day, which was increased to 4 mg/day after the first month. Treatment efficacy was self-sco  ...[more]

Similar Datasets

| S-EPMC6691907 | biostudies-other
| S-EPMC5910539 | biostudies-literature
| S-EPMC8783359 | biostudies-literature
| S-EPMC5712672 | biostudies-literature
| S-EPMC6638990 | biostudies-literature
| S-EPMC4958903 | biostudies-literature
| S-EPMC4749092 | biostudies-literature
| S-EPMC8607557 | biostudies-literature
| S-EPMC6315046 | biostudies-other
| S-EPMC6886496 | biostudies-literature